Search for atoxic cereals: a single blind, cross-over study on the safety of a single dose of Triticum monococcum, in patients with celiac disease

Barbara Zanini, Beatrice Petroboni, Tarcisio Not, Nicola Di Toro, Vincenzo Villanacci, Francesco Lanzarotto, Norberto Pogna, Chiara Ricci, Alberto Lanzini, Barbara Zanini, Beatrice Petroboni, Tarcisio Not, Nicola Di Toro, Vincenzo Villanacci, Francesco Lanzarotto, Norberto Pogna, Chiara Ricci, Alberto Lanzini

Abstract

Background: Cereals of baking quality with absent or reduced toxicity are actively sought as alternative therapy to a gluten-free diet (GFD) for patients with coeliac disease (CD). Triticum monococcum, an ancient wheat, is a potential candidate having no toxicity in in-vitro and ex-vivo studies. The aim of our study was to investigate on the safety of administration of a single dose of gluten of Tm in patients with CD on GFD.

Methods: We performed a single blind, cross-over study involving 12 CD patients who had been on a GFD for at least 12 months, challenged on day 0, 14 and 28 with a single fixed dose of 2.5 grams of the following (random order): Tm, rice (as reference atoxic protein) and Amygluten (as reference toxic protein) dispersed in a gluten-free pudding. The primary end-point of the study was the change in intestinal permeability, as assessed by changes in the urinary lactulose/rhamnose ratio (L/R ratio) measured by High Pressure Liquid Chromatography. We also assessed the occurrence of adverse gastrointestinal events, graded for intensity and duration according to the WHO scale. Variables were expressed as mean ± SD; paired t-test and χ² test were used as appropriate.

Results: The urinary L/R ratio did not change significantly upon challenge with the 3 cereals, and was 0.055 ± 0.026 for Tm Vs 0.058 ± 0.035 for rice (p = 0.6736) and Vs 0.063 ± 0.054 with Amygluten (p = 0.6071). Adverse gastrointestinal events were 8 for Tm, Vs 11 for rice (p = 0.6321) and Vs 31 for Amygluten p = 0.0016), and, in all cases events were graded as "mild" or "moderate" with TM and rice, and as "severe" or "disabling" in 4 cases during Amygluten.

Conclusions: No definite conclusion can be drawn on the safety of Tm, based on no change in urinary L/R because even Amygluten, a toxic wheat protein, did not cause a significant change in urinary L/R indicating low sensitivity of this methodology in studies on acute toxicity. Tm was, however, well tolerated by all patients providing the rationale for further investigation on the safety of this cereal for CD patients.

Trial registration: EudraCT-AIFA n2008-000697-20.

Figures

Figure 1
Figure 1
Reproducibility on 2 successive days of urinary lactulose/rhamnose ratio (L/R) as an index of intestinal permeability in (A) healthy controls and (B) celiac patients.
Figure 2
Figure 2
Effect of acute challenge with 2.5 g of rice protein, Triticum monococcum protein and Amygluten on changes of intestinal permeability as measured by urinary lactulose/rhamnose ratio (L/R) ratio in celiac patients on gluten free diet.

References

    1. Fasano A, Catassi C. Clinical practice. Celiac disease. N Engl J Med. 2012;367:2419–2426. doi: 10.1056/NEJMcp1113994.
    1. Whitaker JK, West J, Holmes GK, Logan RF. Patient perceptions of the burden of coeliac disease and its treatment in the UK. Aliment Pharmacol Ther. 2009;29:1131–1136. doi: 10.1111/j.1365-2036.2009.03983.x.
    1. Lee AR, Ng DL, Diamond B, Ciaccio EJ, Green PH. Living with coeliac disease: survey results from the U.S.A. J Hum Nutr Diet. 2012;25:233–238. doi: 10.1111/j.1365-277X.2012.01236.x.
    1. Rashtak S, Murray JA. Review article: coeliac disease, new approaches to therapy. Aliment Pharmacol Ther. 2012;35:768–781. doi: 10.1111/j.1365-2036.2012.05013.x.
    1. Molberg O, Uhlen AK, Jensen T, Flaete NS, Fleckenstein B, Arentz-Hansen H, Raki M, Lundin KE, Sollid LM. Mapping of gluten T-cell epitopes in the bread wheat ancestors: implications for celiac disease. Gastroenterology. 2005;128:393–401. doi: 10.1053/j.gastro.2004.11.003.
    1. Spaenij-Dekking L, Kooy-Winkelaar Y, van VP, Drijfhout JW, Jonker H, van SL, Smulders MJ, Bosch D, Gilissen LJ, Koning F. Natural variation in toxicity of wheat: potential for selection of nontoxic varieties for celiac disease patients. Gastroenterology. 2005;129:797–806. doi: 10.1053/j.gastro.2005.06.017.
    1. De Vincenzi M, Vincentini O, Di NG, Boirivant M, Gazza L, Pogna N. Two prolamin peptides from durum wheat preclude celiac disease-specific T cell activation by gluten proteins. Eur J Nutr. 2010;49:251–255. doi: 10.1007/s00394-009-0080-4.
    1. De Vincenzi M, Luchetti R, Giovannini C, Pogna NE, Saponaro C, Galterio G, Gasbarrini G. In vitro toxicity testing of alcohol-soluble proteins from diploid wheat Triticum monococcum in celiac disease. J Biochem Toxicol. 1996;11:313–318. doi: 10.1002/(SICI)1522-7146(1996)11:6<313::AID-JBT7>;2-N.
    1. De Vincenzi M, Stammati A, Luchetti R, Silano M, Gasbarrini G, Silano V. Structural specificities and significance for coeliac disease of wheat gliadin peptides able to agglutinate or to prevent agglutination of K562(S) cells. Toxicology. 1998;127:97–106. doi: 10.1016/S0300-483X(98)00034-1.
    1. De Vincenzi M, Dessi MR, Giovannini C, Maialetti F, Mancini E. Agglutinating activity of wheat gliadin peptide fractions in celiac-disease. Toxicology. 1995;96:29–35. doi: 10.1016/0300-483X(94)02912-E.
    1. Pizzuti D, Buda A, D’Odorico A, D’Inca R, Chiarelli S, Curioni A, Martines D. Lack of intestinal mucosal toxicity of Triticum monococcum in celiac disease patients. Scand J Gastroenterol. 2006;41:1305–1311. doi: 10.1080/00365520600699983.
    1. Gianfrani C, Maglio M, Rotondi AV, Camarca A, Vocca I, Iaquinto G, Giardullo N, Pogna N, Troncone R, Auricchio S, Mazzarella G. Immunogenicity of monococcum wheat in celiac patients. Am J Clin Nutr. 2012;96:1339–1345. doi: 10.3945/ajcn.112.040485.
    1. Greco L, D’Adamo G, Truscelli A, Parrilli G, Mayer M, Budillon G. Intestinal permeability after single dose gluten challenge in coeliac disease. Arch Dis Child. 1991;66:870–872. doi: 10.1136/adc.66.7.870.
    1. Zanini B, Lanzarotto F, Mora A, Bertolazzi S, Turini D, Cesana B, Donato F, Ricci C, Lonati F, Vassallo F, Scarcella C, Lanzini A. Five year time course of celiac disease serology during gluten free diet: results of a community based “CD-Watch” program. Dig Liver Dis. 2010;42:865–870. doi: 10.1016/j.dld.2010.05.009.
    1. Edwards IR, Biriell C. Harmonisation in pharmacovigilance. Drug Saf. 1994;10:93–102. doi: 10.2165/00002018-199410020-00001.
    1. Paterson BM, Lammers KM, Arrieta MC, Fasano A, Meddings JB. The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study. Aliment Pharmacol Ther. 2007;26:757–766. doi: 10.1111/j.1365-2036.2007.03413.x.
    1. Leffler DA, Kelly CP, Abdallah HZ, Colatrella AM, Harris LA, Leon F, Arterburn LA, Paterson BM, Lan ZH, Murray JA. A randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during gluten challenge. Am J Gastroenterol. 2012;107:1554–1562. doi: 10.1038/ajg.2012.211.
    1. Kelly CP, Green PH, Murray JA, Dimarino A, Colatrella A, Leffler DA, Alexander T, Arsenescu R, Leon F, Jiang JG, Arterburn LA, Paterson BM, Fedorak RN. Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study. Aliment Pharmacol Ther. 2013;37:252–262. doi: 10.1111/apt.12147.
    1. Katouzian F, Sblattero D, Not T, Tommasini A, Giusto E, Meiacco D, Stebel M, Marzari R, Fasano A, Ventura A. Dual sugar gut-permeability testing on blood drop in animal models. Clin Chim Acta. 2005;352:191–197. doi: 10.1016/j.cccn.2004.09.023.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다